Marcus Miller Beacon
AI Clinical Synthesis & Staging
View Original Clinical Notes Entered
67-year-old male with unresectable Stage IIIB NSCLC. Completed chemoradiation 8 months ago. Recent CT shows local thoracic recurrence. EGFR Exon 19 deletion positive. ECOG 1.
Key Eligibility Checklist
Top Matched Clinical Trials
Ranked by AI matching score against protocol inclusion and exclusion criteria.
Phase 2 Study of Targeted Combination Therapy in EGFR-Mutated Advanced NSCLC
A prospective open-label Phase 2 study evaluating third-generation EGFR TKI in combination with bispecific antibody therapy in patients with advanced non-small cell lung cancer harboring sensitizing EGFR mutations following frontline disease progression.
- ✓ Matches EGFR Exon 19 deletion
- ✓ Eligible with prior 1st-generation TKI progression
- ✓ Permits treated asymptomatic CNS metastases
- ✓ Local trial center within 5 miles
Study of Novel Brain-Penetrant TKI in Patients with EGFR-Mutant NSCLC and CNS Metastases
Evaluating efficacy and safety of a next-generation brain-penetrant kinase inhibitor in metastatic NSCLC patients with documented active or treated intracranial lesions.
- ✓ Matches EGFR mutation and Stage IV staging
- ✓ Directly targets intracranial disease stability
- ✓ Center in Boston medical area
Subsequent-Line Bispecific Antibody vs Chemotherapy in Pretreated Non-Small Cell Lung Cancer
Phase 3 randomized multicenter trial comparing dual-specific immunotherapy versus standard pemetrexed chemotherapy in pretreated metastatic lung adenocarcinoma.
- ✓ Eligible for second-line systemic therapy
- ✓ Acceptable organ metrics and performance status